U.S. Health Secretary Robert F. Kennedy Jr. has named eight new members to the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), following the abrupt dismissal of all 17 prior members. The newly appointed panel includes several figures known for expressing skepticism about vaccines, particularly mRNA technology.
Among the new appointees is Robert Malone, a vocal critic of mRNA COVID-19 vaccines and an ally of Kennedy’s "Make America Healthy Again" movement. Other members include Joseph Hibbeln, Martin Kulldorff, Retsef Levi, Cody Meissner, James Pagano, Vicky Pebsworth, and Michael Ross—some of whom have ties to prior CDC or FDA vaccine panels, while others have promoted views critical of current vaccination practices.
Kennedy, who has long challenged vaccine safety despite scientific consensus, claimed the former panel had conflicts of interest, although he did not provide specific evidence. He emphasized the reshuffle was meant to “restore public trust in vaccine science.”
The new ACIP members will participate in the committee’s June 25–27 meeting, where decisions are expected on vaccine recommendations for flu shots and the 2025–26 COVID-19 boosters. The meeting agenda has yet to be released.
The move sparked market reactions: Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE) shares dipped slightly, while Novavax (NASDAQ:NVAX), which produces a non-mRNA COVID-19 vaccine, saw a marginal rise.
Concerns remain about the vetting process for the new members. Some, like Pebsworth and Meissner, have served on FDA advisory committees, while others, such as Levi and Kulldorff, have made controversial statements questioning mRNA vaccine safety.
Despite FDA confirmation that mRNA vaccines are safe and effective, Kennedy’s overhaul has intensified the national debate on vaccine policy and public health strategy.


Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss
What ‘Taiwan Independence’ Means as Xi Presses Trump on US Policy
McDonald’s Sees Flat Traffic, Sticky Inflation as New Normal
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping
France Defends Netanyahu Airspace Clearance Despite ICC Warrant
BlackBerry Shares Rise as Q2 Earnings, Revenue Beat Estimates
South Korea, US Discuss Warship Building Cooperation
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals
SoftBank Shares Fall as Oracle Flags Stargate Data Center Delay Risk
3 clinical-grade skincare creams you really shouldn’t buy online
Trump Asks Supreme Court to Restore Third-Country Deportations
SMBC Eyes 20% VPBank Stake in Vietnam Expansion
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
Netanyahu Takes Aim at Mamdani as Israel Election Nears
North Korea Rejects Nuclear Test Warning, Calls Nuclear Status Irreversible
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 



